search
Back to results

Effect of Vildagliptin on Fat and Muscle Metabolism in Patients With Type 2 Diabetes

Primary Purpose

Diabetes Mellitus, Type 2

Status
Completed
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
Vildagliptin
Sponsored by
Novartis
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diabetes Mellitus, Type 2 focused on measuring Vildagliptin, Type 2 diabetes

Eligibility Criteria

30 Years - 65 Years (Adult, Older Adult)All Sexes

Inclusion Criteria:

  • Must be able to complete a 3-week wash-out of current anti-diabetic medication
  • Cannot take any medications which may alter gastric motility except for cardiac medication at a stable dose
  • Must discontinue beta-blockers and lipid lowering drugs
  • Blood glucose criteria must be met
  • BMI in the range 30-35

Exclusion Criteria:

  • History of type 1 diabetes, diabetes resulting from pancreatic injury, or secondary forms of diabetes
  • Need for insulin within 3 months or patients on thiazolidinediones
  • Patients taking a sulfonylurea or metformin who cannot safely discontinue medication for the duration of the study
  • Significant concomitant disease or complications of diabetes
  • Patients with any history of gastrointestinal surgery or positive gastrointestinal symptons
  • High tryglycerides as defined by the protocol
  • Smokers who cannot abstain from smoking during the treatment periods

Sites / Locations

  • Novartis Pharmaceuticals
  • Novartis Investigative Site

Outcomes

Primary Outcome Measures

To explore whether vildagliptin augments insulin mediated inhibition of adipose tissue lipid mobilization following a mixed meal in patients with type 2 diabetes

Secondary Outcome Measures

To measure the effects of vildagliptin on tissue carbohydrate metabolism (skeletal muscle)

Full Information

First Posted
September 22, 2006
Last Updated
February 20, 2017
Sponsor
Novartis
search

1. Study Identification

Unique Protocol Identification Number
NCT00380445
Brief Title
Effect of Vildagliptin on Fat and Muscle Metabolism in Patients With Type 2 Diabetes
Official Title
Effect of Vildagliptin on Adipose Tissue and Skeletal Muscle Metabolism in Obese Patients With Type 2 Diabetes
Study Type
Interventional

2. Study Status

Record Verification Date
February 2017
Overall Recruitment Status
Completed
Study Start Date
January 2006 (undefined)
Primary Completion Date
April 2007 (Actual)
Study Completion Date
April 2007 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Novartis

4. Oversight

5. Study Description

Brief Summary
Please note this study is not being conducted in the United States. The purpose of this study is to test the hypothesis that acute DPP-4 inhibition with vildagliptin improves fat and muscle metabolism in patients with type 2 diabetes mellitus.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Type 2
Keywords
Vildagliptin, Type 2 diabetes

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Crossover Assignment
Masking
Double
Allocation
Randomized
Enrollment
21 (Actual)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
Vildagliptin
Primary Outcome Measure Information:
Title
To explore whether vildagliptin augments insulin mediated inhibition of adipose tissue lipid mobilization following a mixed meal in patients with type 2 diabetes
Secondary Outcome Measure Information:
Title
To measure the effects of vildagliptin on tissue carbohydrate metabolism (skeletal muscle)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
30 Years
Maximum Age & Unit of Time
65 Years
Eligibility Criteria
Inclusion Criteria: Must be able to complete a 3-week wash-out of current anti-diabetic medication Cannot take any medications which may alter gastric motility except for cardiac medication at a stable dose Must discontinue beta-blockers and lipid lowering drugs Blood glucose criteria must be met BMI in the range 30-35 Exclusion Criteria: History of type 1 diabetes, diabetes resulting from pancreatic injury, or secondary forms of diabetes Need for insulin within 3 months or patients on thiazolidinediones Patients taking a sulfonylurea or metformin who cannot safely discontinue medication for the duration of the study Significant concomitant disease or complications of diabetes Patients with any history of gastrointestinal surgery or positive gastrointestinal symptons High tryglycerides as defined by the protocol Smokers who cannot abstain from smoking during the treatment periods
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Novartis Pharmaceuticals
Organizational Affiliation
Novartis Pharmaceuticals
Official's Role
Study Director
Facility Information:
Facility Name
Novartis Pharmaceuticals
City
East Hanover
State/Province
New Jersey
ZIP/Postal Code
07936
Country
United States
Facility Name
Novartis Investigative Site
City
Investigative Centers
Country
Germany

12. IPD Sharing Statement

Citations:
PubMed Identifier
19088168
Citation
Boschmann M, Engeli S, Dobberstein K, Budziarek P, Strauss A, Boehnke J, Sweep FC, Luft FC, He Y, Foley JE, Jordan J. Dipeptidyl-peptidase-IV inhibition augments postprandial lipid mobilization and oxidation in type 2 diabetic patients. J Clin Endocrinol Metab. 2009 Mar;94(3):846-52. doi: 10.1210/jc.2008-1400. Epub 2008 Dec 16.
Results Reference
result

Learn more about this trial

Effect of Vildagliptin on Fat and Muscle Metabolism in Patients With Type 2 Diabetes

We'll reach out to this number within 24 hrs